Dana Corsen

• Manage all public payer and policy related issues through direct staff of Field Managers, Market Access and Government Affairs (West, Central and East Canada) • Oversee all AbbVie provincial payer reimbursement files. Support the development and implementation of annual plan for all public payer customer plans in Canada. • Oversee all provinces healthcare payer policy & reimbursement files.

I held this position until November 2024 Oversaw national (ex-Quebec) team in development and implementation of integrated regional access strategies, policy initiatives, and advocacy campaigns as member of leadership group. Secured optimal provincial and federal coverage for J&J portfolio of products with public payers. • Led cross-functional teams and provided strategic counsel for access maintenance, market entry preparations, patient program implementation, and negotiation planning for 15+ products and 25+ unique indications in oncology and specialty medicines • Served as tenured member of Ontario Innovative Medicines Canada industry team, leading work on accelerated patient access pathways, product listing red-tape reduction, precision medicine testing, rare disease funding, and life sciences economic sector strategy.

• Primary lead responsible for maintaining and securing Ontario public reimbursement for the entire JnJ portfolio of products in the Oncology & Specialty market including payer relations, submissions, negotiations and listing pull through. • Cross-functional leadership and valued contributor to several local and global level GR/Access related initiatives including precision medicine, value-based healthcare and biosimilar policy.

• Directed and enabled a broad range of vital market access strategy and policy initiatives including key stakeholder engagement to shape and successfully secure timely patient access to innovative treatments and maintenance of reimbursement for late lifecycle products across the Oncology and Specialty portfolio. • Built and fostered a broad range of vital stakeholder relationships at the political, public administration and health system leader level to positively shape innovation adoption, healthcare system reform and a positive market access landscape while successfully demonstrating a valued role for the life sciences sector as an economic driver.

• Conceptualized and directed the creation of national therapeutic policy strategies advocating for and demonstrating value based healthcare principles for the adoption of innovation to support health care system sustainability • Facilitating positive market entry and access conditions for pipeline products in Precision Medicine, CNS, Hemophilia & Ophthalmology.

• Managed strategic cross-functional product lifecycle teams including oversight of launch readiness, annual business planning, commercial budget, P&L accountability and overall marketing management. • • Increasing responsibility and brand leadership across Oncology portfolio in Melanoma, Lung & Hematology portfolio of precision medicines • Exceeding revenue and profitability targets while setting new Oncology treatment and diagnostic standards and better outcomes for patients.

• Oversaw and managed full commercial life cycle, strategic business planning, DME budget, and P&L accountability for Breast cancer portfolio. • Strategically led deployment for $50M in sales exceeding revenue and profitability targets.

• Led strategic planning, development and execution of most important commercial indication launch for largest and most critical corporate brand - CRESTOR ($625M in sales for 2010). • Led deployment of JUPITER indication launch plan resulting in 24% YOY growth and unprecedented 2.2% TRx market share lift in largest existing pharmaceutical class against largest generic market entry LIPITOR in the same fiscal quarter.

• Created and executed accredited medical education at a National level for the most critical portfolio to the company. Oversaw strategic deployment of $1.5M yearly Medical Education budget. • Managed field educational plans related to 45 sales territories ensuring brand strategy was cohesively synergized to achieve National sales targets while delivering regional leadership and perspective to optimize patient care and outcomes.

• Responsible for account oversight of consultative marketing communications and educational initiatives to Rx&D companies on strategic business planning and tactical execution to achieve annual brand sales objectives. • Created, coordinated and executed commercial launch planning workshops, KOL Advisory Boards, CHE Train-the Trainer meetings, Focus Groups and Accredited Educational programs.